Form 4: GT Biopharma Director Acquires Stock Options
Insider Transaction Report
GT Biopharma Director Hilary Kramer reported the acquisition of 31,250 stock options with an exercise price of $1.33.
Summary
- Hilary Kramer, a Director of GT Biopharma, Inc. (GTBP), acquired 31,250 options to purchase common stock.
- The options have an exercise price of $1.33 per share.
- The transaction occurred on September 4, 2025.
- These options are fully vested and immediately exercisable.
- The options expire on August 19, 2035.
- Following this transaction, Hilary Kramer beneficially owns 31,250 derivative securities directly.
Sentiment
Score: 7
Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating alignment with shareholder interests and confidence in the company's future prospects. However, it is a routine insider transaction disclosure.
Positives
- Director Hilary Kramer acquired 31,250 stock options, indicating continued alignment of interests with shareholders.
- The options are fully vested and immediately exercisable, providing immediate potential for value realization.
Future Outlook
NA
Industry Context
This Form 4 filing reports an insider transaction, which is a routine disclosure for public companies. It does not provide broader industry context or trends, but rather details a specific equity acquisition by a director.
Stakeholder Impact
- Shareholders: The acquisition of options by a director aligns their interests with shareholders, potentially signaling confidence in future stock performance.
Key Dates
| Date | Description |
|---|---|
| 09/04/2025 | Date of earliest transaction: Acquisition of stock options. |
| 09/08/2025 | Signature date of the reporting person. |
| 08/19/2035 | Expiration date of the acquired stock options. |
Recommendation
holdThis filing reports a routine insider transaction where a director acquired stock options. While insider buying can be a positive signal, this single transaction, without further context on the company's financial performance or strategic direction, is not sufficient to warrant a strong buy or sell recommendation. Investors should consider this information as one data point among many when evaluating GT Biopharma.
Keywords
GT Biopharma, GTBP, Hilary Kramer, Stock Options, Director, Insider Transaction, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.